Neil Campbell

Life Sciences Transactions Associate

Reed Smith LLP

Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters.

Preclinical Imaging Shared Resource Manager

Rutgers Cancer Institute of New Jersey

Manufacturing and R&D Agreements

• Drafted and negotiated multiple complex development and manufacturing agreements for CAR-T product supply chain of clinical-development stage company client
• Represented early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder
• Drafted and negotiated sponsored research and other agreements with academic institutions in the USA, EU, and UK
• Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products

Licensing and Collaboration Transactions

• Multiple early-stage, venture-backed drug development companies in research collaborations to discover and/or generate multi-specific or conjugated antibodies directed against designated drug targets
• EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multi-specific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales
• TMS Co., Ltd. in a strategic collaboration agreement with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING
• ONK Therapeutics in a license and collaboration with Intellia to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M plus royalties
• Immunocore Holdings in a research and development collaboration with Gaeta B.V. to develop gamma delta (γδ) TCR-based immunotherapies for solid tumors, with an option for Immunocore to exclusively license candidates resulting from the collaboration
• Alnylam in a License Agreement with Agios for novel siRNA for potential

Neil is a member of the Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance.